540 results on '"Presley, Carolyn"'
Search Results
202. Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Right Treatment for the Right Patient
- Author
-
Presley, Carolyn J., primary, Gross, Cary P., additional, and Lilenbaum, Rogerio C., additional
- Published
- 2016
- Full Text
- View/download PDF
203. Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab.
- Author
-
Khorasanchi, Adam, Zhao, Songzhu, Wei, Lai, Li, Mingjia, Ho, Kevin, Abu-Sbeih, Hamzah, Alexander, John Howard, Goodyear, Evelyn, Secor, Austin, Shields, Peter G., He, Kai, Kaufman, Jacob, Memmott, Regan Michelle, Alahmadi, Asrar, Carbone, David Paul, Otterson, Gregory Alan, Meara, Alexa Simon, Presley, Carolyn J, and Owen, Dwight Hall
- Published
- 2023
- Full Text
- View/download PDF
204. Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).
- Author
-
Li, Mingjia, Zhao, Songzhu, Chian, Kenneth, Kwon, Hyunwoo, Jones, Nicholas, Khorasanchi, Adam, Gauntner, Timothy, Coss, Christopher C., Phelps, Mitch A., Spakowicz, Daniel, Wei, Lai, Alahmadi, Asrar, Memmott, Regan Michelle, Kaufman, Jacob, He, Kai, Shields, Peter G., Carbone, David Paul, Otterson, Gregory Alan, Presley, Carolyn J, and Owen, Dwight Hall
- Published
- 2023
- Full Text
- View/download PDF
205. Real world outcomes of patients treated with first line chemo-immunotherapy (IO) for small cell lung cancer (SCLC): Impact of brain metastases and patterns of subsequent therapy.
- Author
-
Farid, Saira, Zhao, Songzhu, Patel, Sandip, Travis, Kaylee, Addison, Sarah, Wei, Lai, Li, Mingjia, Palmer, Joshua David, Beyer, Sasha, Raval, Raju R., Shields, Peter G., He, Kai, Kaufman, Jacob, Memmott, Regan Michelle, Alahmadi, Asrar, Carbone, David Paul, Otterson, Gregory Alan, Presley, Carolyn J., and Owen, Dwight Hall
- Published
- 2023
- Full Text
- View/download PDF
206. Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva).
- Author
-
Sharp, John, Zhao, Songzhu, Patel, Sandip, Wei, Lai, Li, Mingjia, Brownstein, Jeremy, WELLIVER, Meng Xu, Haglund, Karl, Palmer, Joshua David, Beyer, Sasha, Raval, Raju R., Shields, Peter G., He, Kai, Kaufman, Jacob, Memmott, Regan Michelle, Alahmadi, Asrar, Carbone, David Paul, Otterson, Gregory Alan, Presley, Carolyn J, and Owen, Dwight Hall
- Published
- 2023
- Full Text
- View/download PDF
207. Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.
- Author
-
Kwon, Hyunwoo, Li, Mingjia, Chian, Kenneth, Gauntner, Timothy, Jones, Nicholas, Khorasanchi, Adam, Spakowicz, Daniel, Lopez, Gabrielle, Goodyear, Evelyn, Secor, Austin, He, Kai, Alahmadi, Asrar, Memmott, Regan Michelle, Kaufman, Jacob, Shields, Peter G., Carbone, David Paul, Otterson, Gregory Alan, Presley, Carolyn J, Li, Zihai, and Owen, Dwight Hall
- Published
- 2023
- Full Text
- View/download PDF
208. Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.
- Author
-
Abu-Sbeih, Hamzah, Moodabagil, Meghana, Peng, Jing, Ma, Jianing, Easterling, Robert, Viveiros, Matthew, Li, Mingjia, Secor, Austin, Goodyear, Evelyn, Kendra, Kari Lynn, Otterson, Gregory Alan, Presley, Carolyn J, Donnelly, Edwin, Meara, Alexa Simon, Owen, Dwight Hall, and Ho, Kevin
- Published
- 2023
- Full Text
- View/download PDF
209. Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.
- Author
-
Kaufman, Jacob, Owen, Dwight Hall, Memmott, Regan Michelle, Otterson, Gregory Alan, He, Kai, Presley, Carolyn J, Spakowicz, Daniel, Shields, Peter G., Zhang, Xiaoli, Boyle, Theresa A., Cress, W. Douglas, Wood, Kris, Ready, Neal E., Li, Lang, Li, Zihai, and Carbone, David Paul
- Published
- 2023
- Full Text
- View/download PDF
210. Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.
- Author
-
Lee, Howard Jinsoo, Walter, Louise Christie, Smith, Alexander K., Shi, Ying, Boscardin, W. John, Cohen, Harvey Jay, Williams, Grant Richard, Zeng, Sandra, Presley, Carolyn J, Magnuson, Allison, Mohile, Supriya Gupta, Singhal, Surbhi, Ursem, Carling Jade, Velazquez Manana, Ana I., Gubens, Matthew A., Blakely, Collin M., Mulvey, Claire, Allen, Greg M., Ostrem, Jonathan, and Wong, Melisa L.
- Published
- 2023
- Full Text
- View/download PDF
211. Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
- Author
-
Wong, Alex, Riley, Maria, Zhao, Songzhu, Wang, Jing Gennie, Esguerra, Vince, Li, Mingjia, Lopez, Gabrielle, Otterson, Gregory A., Kendra, Kari, Presley, Carolyn J., Wei, Lai, Owen, Dwight H., and Ho, Kevin
- Subjects
IMMUNE checkpoint inhibitors ,PNEUMONIA ,IPILIMUMAB ,ACADEMIC medical centers ,HUMAN abnormalities ,CRITICAL care medicine - Abstract
Dwight H. Owen affiliation should be Division of Medical Oncology, Department of Internal Medicine, The Ohio State University - James Comprehensive Cancer Center, Columbus, OH, USA. Correction: Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis Kevin Ho affiliation should be Division of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University Wexner Medical Center, 241 W11th Ave, Suite 5000, Columbus, OH 43,201, USA. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
212. Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non‑small cell lung cancer.
- Author
-
Singhi, Eric K., Mott, Frank, Worst, Michelle, Leung, Cheuk Hong, Lee, J. Jack, Carter, Brett, Presley, Carolyn J., Heymach, John V., and Altan, Mehmet
- Subjects
NON-small-cell lung carcinoma ,OLDER patients ,OLDER people ,DISEASE progression ,TREATMENT effectiveness - Abstract
Immunotherapy is an effective and generally well-tolerated treatment strategy for older adult patients (aged ≥70 years) with advanced non-small cell lung cancer (NSCLC). Unfortunately, most patients who receive immunotherapy eventually exhibit disease progression during treatment. The present study reports on a subset of older adult patients with advanced NSCLC who could effectively continue immunotherapy beyond radiographic disease progression due to perceived clinical benefit. Local consolidative radiotherapy may be used in select older adult patients to prolong the duration of immunotherapy they receive, with a particular consideration of their preexisting co-morbidities, performance status and tolerance of potential toxicities associated with combined modality therapy. However, prospective research is needed to determine which patients benefit most from the addition of local consolidative radiotherapy, including whether type of disease progression (i.e., sites of progression, pattern of progression) and/or extent of consolidation offered (i.e., complete or incomplete) impact clinical outcomes. Further research is also warranted to determine which patients would most benefit from the continuation of immunotherapy beyond documented radiographic disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
213. The Treatment of Advanced Lung Cancer in the Elderly
- Author
-
Presley, Carolyn, primary and Lilenbaum, Rogerio, additional
- Published
- 2015
- Full Text
- View/download PDF
214. “The burden upon me”: The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment.
- Author
-
Presley, Carolyn Jean, primary, Soulos, Pamela R., additional, Yu, James B., additional, and Gross, Cary Philip, additional
- Published
- 2015
- Full Text
- View/download PDF
215. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.
- Author
-
Elias, Rawad, Morales, Joshua, and Presley, Carolyn
- Abstract
Non-small cell lung cancer (NSCLC) is mostly a disease of older adults, with its incidence and mortality rates increasing exponentially after the age of 65 years. Immune checkpoint inhibitors (ICIs) have changed the scene of NSCLC treatment after a long and relatively stagnant period of standard treatment regimens. However, little is known about the specific impact of these agents in older adults for whom care is often complicated by a variety of syndromes. This underlines the importance of understanding the dynamics of new cancer treatments in an older patient population. In this paper, we will review ICIs' mechanism of action and data from published clinical trials relevant to older adults. In addition, we will discuss immune aging and treatment-related toxicity as potential challenges facing the use of checkpoint inhibitors in older adults with NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
216. Estimating Cancer Treatment Tolerability for Older Adults With Advanced Cancer—The Holy Grail.
- Author
-
Presley, Carolyn J.
- Published
- 2023
- Full Text
- View/download PDF
217. Change in four measures of physical function among older adults during lung cancer treatment: A mixed methods cohort study.
- Author
-
Singhal, Surbhi, Walter, Louise C., Smith, Alexander K., Loh, Kah Poh, Cohen, Harvey Jay, Zeng, Sandra, Shi, Ying, Boscardin, W. John, Presley, Carolyn J., Williams, Grant R., Magnuson, Allison, Mohile, Supriya G., and Wong, Melisa L.
- Abstract
Functional outcomes during non-small cell lung cancer (NSCLC) treatment are critically important to older adults. Yet, data on physical function and which measures best capture functional change remain limited. This multisite, mixed methods cohort study recruited adults ≥65 years with advanced NSCLC starting systemic treatment (i.e., chemotherapy, immunotherapy, and/or targeted therapy) with non-curative intent. Participants underwent serial geriatric assessments prior to starting treatment and at one, two, four, and six months, which included the Karnofsky Performance Scale (KPS, range: 0–100%), instrumental activities of daily living (IADL, range: 0–14), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Physical Functioning subscale (EORTC QLQ-C30 PF, range: 0–100), and Life-Space Assessment (LSA, range: 0–120). For all measures, higher scores represent better functioning. In a qualitative substudy, 20 patients completed semi-structured interviews prior to starting treatment and at two and six months to explore how treatment affected their daily functioning. We created joint displays for each interview participant that integrated their longitudinal KPS, IADL, EORTC QLQ-C30 PF, and LSA scores with patient quotes describing their function. Among 87 patients, median age was 73 years (range 65–96). Mean pretreatment KPS score was 79% (standard deviation [SD] 13), EORTC QLQ-C30 PF was 69 (SD 23), and LSA was 67 (SD 28); median IADL was 13 (interquartile range [IQR] 10–14). At two months after treatment initiation, 70% of patients experienced functional decline on at least one measure, with only 13% of these patients recovering at six months. At two and six months, decline in LSA was the most common (48% and 35%, respectively). Joint displays revealed heterogeneity in how well each quantitative measure of physical function captured the qualitative patient experience. Functional decline during NSCLC treatment is common among older adults. LSA is a useful measure to detect subtle functional decline that may be missed by other measures. Given heterogeneity in how well each quantitative measure captures changes in physical function, there is value to including more than one functional measure in geriatric oncology research studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
218. End-of-life care trajectories among older adults with lung cancer.
- Author
-
Davidoff, Amy J., Canavan, Maureen E., Prsic, Elizabeth, Saphire, Maureen, Wang, Shi-Yi, and Presley, Carolyn J.
- Abstract
Medicare decedents with cancer often receive intensive care during the last month of life; however, little information exists on longer end-of-life care trajectories. Using SEER-Medicare data, we selected older adults diagnosed with lung cancer between 2008 and 2013 who survived at least six months and died between 2008 and 2014. Each month we assessed claims to assign care categories ordered by intensity as follows: full-month inpatient/skilled nursing facility > cancer-directed therapy (CDT) only > concurrent CDT and symptom management and supportive care services (SMSCS) > SMSCS only > full-month hospice. We assigned each decedent to one of six trajectories: stable hospice, stable SMSCS, stable CDT with or without concurrent SMSCS, decreasing intensity, increasing intensity, and mixed. Multinomial logistic regression estimated associations between socio-demographics, calendar year, and area hospice use rates with end-of-life trajectory. The sample (N = 24,342) was predominantly aged ≥75 years (59.4%) and non-Hispanic White (80.5%); 19.1% lived in healthcare referral regions where ≤50% of cancer decedents received hospice care. Overall, 6.5% were continuously hospice enrolled, 25.6% received SMSCS only, and 29.4% experienced decreasing intensity; 3.9% received CDT or concurrent care, while 8.7% experienced an increase in intensity. Higher healthcare referral region hospice rates were associated with decreasing end-of-life intensity; Black, non-Hispanic decedents had a higher risk of increasing intensity and mixed patterns. Among older decedents with lung cancer, 62% had six-month end-of-life trajectories indicating low or decreasing intensity, but few received persistent CDT. Demographic characteristics, including race/ethnicity, and contextual measures, including area hospice use patterns, were associated with end-of-life trajectory. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
219. Reply to L.W. Cuttino et al
- Author
-
Presley, Carolyn J., primary, Soulos, Pamela R., additional, Herrin, Jeph, additional, Roberts, Kenneth B., additional, Yu, James B., additional, and Gross, Cary P., additional
- Published
- 2013
- Full Text
- View/download PDF
220. A new approach to understanding racial disparities in prostate cancer treatment
- Author
-
Presley, Carolyn J., primary, Raldow, Ann C., additional, Cramer, Laura D., additional, Soulos, Pamela R., additional, Long, Jessica B., additional, Yu, James B., additional, Makarov, Danil V., additional, and Gross, Cary P., additional
- Published
- 2013
- Full Text
- View/download PDF
221. Gaps in nutritional research among older adults with cancer.
- Author
-
Presley, Carolyn J., Dotan, Efrat, Soto-Perez-de-Celis, Enrique, Jatoi, Aminah, Mohile, Supriya G., Won, Elizabeth, Alibhai, Shabbir, Kilari, Deepak, Harrison, Robert, Klepin, Heidi D., Wildes, Tanya M., Mustian, Karen, and Demark-Wahnefried, Wendy
- Abstract
Nutritional issues among older adults with cancer are an understudied area of research despite significant prognostic implications for treatment side effects, cancer-specific mortality, and overall survival. In May of 2015, the National Cancer Institute and the National Institute on Aging co-sponsored a conference focused on future directions in geriatric oncology research. Nutritional research among older adults with cancer was highlighted as a major area of concern as most nutritional cancer research has been conducted among younger adults, with limited evidence to guide the care of nutritional issues among older adults with cancer. Cancer diagnoses among older adults are increasing, and the care of the older adult with cancer is complicated due to multimorbidity, heterogeneous functional status, polypharmacy, deficits in cognitive and mental health, and several other non-cancer factors. Due to this complexity, nutritional needs are dynamic, multifaceted, and dependent on the clinical scenario. This manuscript outlines the proceedings of this conference including knowledge gaps and recommendations for future nutritional research among older adults with cancer. Three common clinical scenarios encountered by oncologists include (1) weight loss during anti-cancer therapy, (2) malnutrition during advanced disease, and (3) obesity during survivorship. In this manuscript, we provide a brief overview of relevant cancer literature within these three areas, knowledge gaps that exist, and recommendations for future research. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
222. Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting.
- Author
-
Kilari, Deepak, Soto-Perez-de-Celis, Enrique, Mohile, Supriya Gupta, Alibhai, Shabbir M.H., Presley, Carolyn J., Wildes, Tanya M., Klepin, Heidi D., Demark-Wahnefried, Wendy, Jatoi, Amina, Harrison, Robert, Won, Elizabeth, and Mustian, Karen M.
- Abstract
Cancer and its treatment can lead to a myriad of adverse events and negatively impact quality of life of older cancer patients and survivors. Unmet physical activity needs vary across the cancer continuum and remain an important yet understudied area of research in this population. Exercise interventions have been shown to be effective in treating both the physical and psychological declines associated with cancer and its treatment, with a potential to improve cancer-related outcomes. Despite the current evidence, exercise is clearly underutilized due to several barriers and knowledge gaps in existing trials that include appropriate population identification, design, and outcome measures selection. The benefits of regular exercise in both the primary and secondary prevention of chronic conditions are well established in the non-cancer population. In older cancer patients and survivors, further research is needed before exercise gains widespread acceptance. The Cancer and Aging Research Group convened experts in exercise, aging and cancer to evaluate current scientific evidence and knowledge gaps in geriatric exercise oncology. This report summarizes these findings and provides future research directions. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
223. Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009
- Author
-
Presley, Carolyn J., primary, Soulos, Pamela R., additional, Herrin, Jeph, additional, Roberts, Kenneth B., additional, Yu, James B., additional, Killelea, Brigid, additional, Lesnikoski, Beth-Ann, additional, Long, Jessica B., additional, and Gross, Cary P., additional
- Published
- 2012
- Full Text
- View/download PDF
224. Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009.
- Author
-
Presley, Carolyn J., primary, Soulos, Pamela R., additional, Herrin, Jeph, additional, Roberts, Kenneth B, additional, Yu, James B., additional, Killelea, Brigid K., additional, Lesnikoski, Beth-Ann, additional, Long, Jessica B., additional, and Gross, Cary P., additional
- Published
- 2012
- Full Text
- View/download PDF
225. Pre-Transplant Geriatric Assessment (GA) with Intervention Among Allogeneic Transplant Recipients
- Author
-
Wall, Sarah A., Funderburg, Allesia, Huang, Ying, Elder, Patrick, Stevens, Erin, Folefac, Edmund, Presley, Carolyn, and Rosko, Ashley
- Published
- 2022
- Full Text
- View/download PDF
226. Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non–Small Cell Lung Cancer.
- Author
-
Obeng-Gyasi, Samilia, Li, Yaming, Carson, William E., Reisenger, Sarah, Presley, Carolyn J., Shields, Peter G., Carbone, David P., Ceppa, DuyKhanh P., Carlos, Ruth C., and Andersen, Barbara L.
- Published
- 2022
- Full Text
- View/download PDF
227. Functional Trajectories and Resilience Among Adults With Advanced Lung Cancer
- Author
-
Presley, Carolyn J., Arrato, Nicole A., Shields, Peter G., Carbone, David P., Wong, Melisa L., Benedict, Jason, Reisinger, Sarah A., Han, Ling, Gill, Thomas M., Allore, Heather, Andersen, Barbara L., and Janse, Sarah
- Abstract
To evaluate whether and the degree to which patients with advanced NSCLC (aNSCLC) receiving lung cancer treatments will experience functional disability or have resilience and to identify characteristics associated with functional disability.
- Published
- 2022
- Full Text
- View/download PDF
228. A video intervention to improve patient understanding of tumor genomic testing in patients with cancer.
- Author
-
Veney, Deloris J., Wei, Lai Y., Toland, Amanda E., Presley, Carolyn J., Hampel, Heather L., Padamsee, Tasleem J., Lee, Clara N., Irvin, William J., Bishop, Michael J., Kim, James J., Hovick, Shelly R., Senter, Leigha A., and Stover, Daniel G.
- Subjects
- *
PATIENT education , *CANCER education , *TUMOR markers , *METASTASIS , *CANCER patients - Abstract
Introduction: Tumor genomic testing (TGT) is standard‐of‐care for most patients with advanced/metastatic cancer. Despite established guidelines, patient education prior to TGT is frequently omitted. The purpose of this study was to evaluate the impact of a concise 4 min video for patient education prior to TGT. Methods: Based on a quality improvement cycle, an animated video was created to be applicable to any cancer type, incorporating culturally diverse images, available in English and Spanish. Patients undergoing standard‐of‐care TGT were enrolled at a tertiary academic institution and completed survey instruments prior to video viewing (T1) and immediately post‐viewing (T2). Instruments included: (1) 10‐question objective genomic knowledge; (2) 10‐question video message‐specific knowledge; (3) 11‐question Trust in Provider; (4) attitudes regarding TGT. Results: A total of 150 participants were enrolled. For the primary objective, there was a significant increase in video message‐specific knowledge (median 10 point increase; p < 0.0001) with no significant change in genomic knowledge/understanding (p = 0.89) or trust in physician/provider (p = 0.59). Results for five questions significantly improved, including the likelihood of TGT impact on treatment decision, incidental germline findings, and cost of testing. Improvement in video message‐specific knowledge was consistent across demographic groups, including age, income, and education. Conclusions: A concise, 3–4 min, broadly applicable video incorporating culturally diverse images administered prior to TGT significantly improved video message‐specific knowledge across all demographic groups. This resource is publicly available at http://www.tumor‐testing.com, with a goal to efficiently educate and empower patients regarding TGT while addressing guidelines within the flow of clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
229. COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis
- Author
-
Bestvina, Christine M., Whisenant, Jennifer G., Torri, Valter, Cortellini, Alessio, Wakelee, Heather, Peters, Solange, Roca, Elisa, De Toma, Alessandro, Hirsch, Fred R., Mamdani, Hirva, Halmos, Balazs, Arrieta, Oscar, Metivier, Anne-Cecile, Fidler, Mary J., Rogado, Jacobo, Presley, Carolyn J., Mascaux, Celine, Genova, Carlo, Blaquier, Juan Bautista, Addeo, Alfredo, Finocchiaro, Giovanna, Khan, Hina, Mazieres, Julien, Morgillo, Floriana, Bar, Jair, Aujayeb, Avinash, Mountzios, Giannis, Scotti, Vieri, Grosso, Federica, Geraedts, Erica, Zhumagaliyeva, Ardak N., Horn, Leora, Garassino, Marina Chiara, and Baena, Javier
- Abstract
The Thoracic Centers International COVID-19 Collaboration (TERAVOLT) registry found ∼ 30% mortality in patients with thoracic malignancies during the initial COVID surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave, and efficacy of vaccination.
- Published
- 2022
- Full Text
- View/download PDF
230. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
- Author
-
Whisenant, Jennifer G., Baena, Javier, Cortellini, Alessio, Huang, Li-Ching, Lo Russo, Giuseppe, Porcu, Luca, Wong, Selina K., Bestvina, Christine M., Hellmann, Matthew D., Roca, Elisa, Rizvi, Hira, Monnet, Isabelle, Boudjemaa, Amel, Rogado, Jacobo, Pasello, Giulia, Leighl, Natasha B., Arrieta, Oscar, Aujayeb, Avinash, Batra, Ullas, Azzam, Ahmed Y., Unk, Mojca, Azab, Mohammed A., Zhumagaliyeva, Ardak N., Gomez-Martin, Carlos, Blaquier, Juan B., Geraedts, Erica, Mountzios, Giannis, Serrano-Montero, Gloria, Reinmuth, Niels, Coate, Linda, Marmarelis, Melina, Presley, Carolyn J., Hirsch, Fred R., Garrido, Pilar, Khan, Hina, Baggi, Alice, Mascaux, Celine, Halmos, Balazs, Ceresoli, Giovanni L., Fidler, Mary J., Scotti, Vieri, Métivier, Anne-Cécile, Falchero, Lionel, Felip, Enriqueta, Genova, Carlo, Mazieres, Julien, Tapan, Umit, Brahmer, Julie, Bria, Emilio, Puri, Sonam, Popat, Sanjay, Reckamp, Karen L., Morgillo, Floriana, Nadal, Ernest, Mazzoni, Francesca, Agustoni, Francesco, Bar, Jair, Grosso, Federica, Avrillon, Virginie, Patel, Jyoti D., Gomes, Fabio, Ibrahim, Ehab, Trama, Annalisa, Bettini, Anna C., Barlesi, Fabrice, Dingemans, Anne-Marie, Wakelee, Heather, Peters, Solange, Horn, Leora, Garassino, Marina Chiara, and Torri, Valter
- Abstract
Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far.
- Published
- 2022
- Full Text
- View/download PDF
231. A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer.
- Author
-
Williams, Terence M., Miller, Eric, Welliver, Meng, Brownstein, Jeremy, Otterson, Gregory, Owen, Dwight, Haglund, Karl, Shields, Peter, Bertino, Erin, Presley, Carolyn, He, Kai, Jacob, Naduparambil K., Walston, Steve, Pan, Jeff, Yang, Xiangyu, Knopp, Michael, Essan, Jean Koutou, McElroy, Joseph, Mo, Xiaokui, and McElroy, Sohyun
- Subjects
- *
FUNCTIONAL magnetic resonance imaging , *STEREOTACTIC radiotherapy , *NON-small-cell lung carcinoma , *OVERALL survival , *RADIATION pneumonitis - Abstract
Primary tumor failure is common in patients treated with chemoradiation (CRT) for locally advanced NSCLC (LA-NSCLC). Stereotactic body radiation therapy (SBRT) yields high rates of primary tumor control (PTC) in early-stage NSCLC. This trial tested an SBRT boost to the primary tumor before the start of CRT to improve PTC. Patients with LA-NSCLC received an SBRT boost in 2 fractions (central location 12 Gy, peripheral location 16 Gy) to the primary tumor, followed by standard CRT (60 Gy in 30 fractions). The primary objective was PTC rate at 1 year, and the hypothesis was that the 1-year PTC rate would be ≥90%. Secondary objectives included objective response rate, regional and distant control, disease-free survival (DFS), and overall survival (OS). Correlative studies included functional magnetic resonance imaging and blood-based miRNA analysis. The study enrolled 21 patients (10 men and 11 women); the median age was 62 years (range, 52-78). The median pretreatment primary tumor size was 5.0 cm (range, 1.0-8.3). The most common nonhematologic toxicities were pneumonitis, fatigue, esophagitis/dysphagia, dyspnea, and cough. Only 1 treatment-related grade 4 nonhematologic toxicity occurred (respiratory failure/radiation pneumonitis), and no grade 5 toxicities occurred. The objective response rate at 3 and 6 months was 72.7% and 80.0%, respectively, and PTC at 1 and 2 years was 100% and 92.3%, respectively. The 2-year regional and distant control rates were 81.6% and 70.3%, respectively. Disease-free survival and overall survival at 2 years were 46.1% and 50.3%, respectively, and median survival was 37.8 months. Functional magnetic resonance imaging detected a mean relative decrease in blood oxygenation level–dependent signal of –87.1% (P =.05), and miR.142.3p was correlated with increased risk of grade ≥3 pulmonary toxicity (P =.01). Dose escalation to the primary tumor using upfront SBRT appears feasible and safe. PTC was high and other oncologic endpoints compared favorably to standard treatment. Functional magnetic resonance imaging suggested changes in oxygenation with the first SBRT boost dose, and miR.142.3p was correlated with pulmonary toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
232. A theoretical explanation for how a nutrition counseling and medically tailored meal delivery program benefitted participants living with lung cancer.
- Author
-
Rothpletz-Puglia, Pamela, Smith, Jade, Pavuk, Chloe, Leotta, Jana, Pike, Kimberli, Presley, Carolyn J., Krok-Schoen, Jessica L., Braun, Ashlea, Cohen, Mary Kathryn, Rogers, Gail T., Chui, Kenneth Kwan Ho, Zhang, Fang Fang, and Spees, Colleen K.
- Abstract
Purpose: The purpose of this study was to assess participants’ perceptions and experiences while participating in a Food is Medicine medically tailored meal plus intensive nutrition counseling intervention to create a theoretical explanation about how the intervention worked. Methods: This interpretive qualitative study included the use of semi-structured interviews with active participants in a randomized controlled trial aimed at understanding how a medically tailored meal plus nutrition counseling intervention worked for vulnerable individuals with lung cancer treated at four cancer centers across the USA. During the 8-month long study, participants in the intervention arm were asked to be interviewed, which were recorded, transcribed verbatim, and analyzed using conventional content analysis with principles of grounded theory. Results: Twenty individuals participated. Data analysis resulted in a theoretical explanation of the intervention’s mechanism of action. The explanatory process includes three linked and propositional categories leading to patient resilience: engaging in treatment, adjusting to diagnosis, and active coping. The medically tailored meals plus nutrition counseling engaged participants throughout treatment, which helped participants adjust to their diagnosis, leading to active coping through intentional self-care, behavior change, and improved quality of life. Conclusions: These findings provide evidence that a Food is Medicine intervention may buffer some of the adversity related to the diagnosis of lung cancer and create a pathway for participants to experience post-traumatic growth, develop resilience, and change behaviors to actively cope with lung cancer. Medically tailored meals plus intensive nutrition counseling informed by motivational interviewing supported individuals’ adjustment to their diagnosis and resulted in perceived positive behavior change. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
233. Lung cancer screening use among screening‐eligible adults with disabilities.
- Author
-
Poghosyan, Hermine, Richman, Ilana, Sarkar, Sayantani, and Presley, Carolyn J.
- Subjects
- *
CROSS-sectional method , *RESEARCH funding , *EARLY detection of cancer , *LOGISTIC regression analysis , *DESCRIPTIVE statistics , *MULTIVARIATE analysis , *LUNG tumors , *COGNITION disorders , *HEARING disorders , *PEOPLE with disabilities - Abstract
Background: Lung cancer screening (LCS) use among adults with disabilities has not been well characterized. We estimated the prevalence of LCS use by disability types and counts and investigated the association between disability counts and LCS utilization among LCS‐eligible adults. Methods: We used cross‐sectional data from the 2019 Behavioral Risk Factor Surveillance System, Lung Cancer Screening Module. Based on the 2013 US Preventive Services Task Force criteria for LCS, the sample included 4407 LCS‐eligible adults, aged 55–79 years, with current or former (quit smoking in the past 15 years) tobacco use history of at least 30 pack‐years. Disability types included limitations in hearing, vision, cognition, mobility, self‐care, and independent living. We also categorized respondents by number of disabilities (no disability, 1 disability, 2 disabilities, 3+ disabilities). We utilized descriptive statistics and multivariable logistic regression analyses to determine the association between disability counts and the receipt of LCS (yes/no) in the past 12 months. Results: In 2019, 16.4% of LCS‐eligible adults were screened for lung cancer. Overall, 49.6% of participants had no disability, and 14.5% had >3 disabilities. Mobility was the most prevalent disability type (35.4%), followed by cognitive impairment (18.2%) and hearing (16.6%). LCS was more prevalent in adults with disability in self‐care versus no disability in self‐care (24.0% vs. 15.5%, p = 0.01), disability in independent living versus no disability in independent living (22.2% vs. 15.4%, p = 0.02), and cognitive impairment disability versus no cognitive impairment (22.1% vs. 15.3%, p = 0.03). The prevalence rates of LCS among groups of LCS‐eligible adults with different disability counts were not significant (p = 0.17). Conclusions: Despite the lack of clinical guidelines on LCS among individuals with disabilities, some individuals with disabilities are being screened for lung cancer. Future research should address this knowledge gap to determine clinical benefit versus harm of LCS among those with disabilities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
234. Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.
- Author
-
Johns, Andrew C., Yang, Mike, Wei, Lai, Grogan, Madison, Patel, Sandipkumar H., Li, Mingjia, Husain, Marium, Kendra, Kari L., Otterson, Gregory A., Burkart, Jarred T., Spakowicz, Daniel, Hoyd, Rebecca, Owen, Dwight H., and Presley, Carolyn J.
- Subjects
- *
CARDIOTOXICITY , *OVERALL survival , *MEDICAL societies , *DRUG side effects , *CARDIOVASCULAR diseases , *IPILIMUMAB - Abstract
Background and objectives: Medical comorbidities (MC) are highly prevalent among patients with cancer and predict worse outcomes for traditional therapies. This association is poorly understood for checkpoint inhibitor immunotherapy (IO). We aimed to explore the relationship between common MC including cardiovascular disease (CVD), immune-related adverse events (irAEs), and overall survival (OS) among patients receiving IO for advanced cancer. Methods: This is a retrospective cohort study of 671 patients with any cancer who received IO at our institution from 2011 to 2018. Clinical data were abstracted via chart review and query of ICD-10 codes and used to calculate modified Charlson comorbidity index (mCCI) scores. The primary outcomes were the association of individual MC with irAEs and OS using bivariate and multivariable analyses. Secondary outcomes included association of mCCI score with irAEs and OS. Results: Among 671 patients, 62.1% had a mCCI score ≥ 1. No individual MC were associated with irAEs or OS. Increased CCI score was associated with decreased OS (p < 0.01) but not with irAEs. Grade ≥ 3 irAEs were associated with increased OS among patients without CVD (HR 0.37 [95% CI: 0.25, 0.55], p < 0.01), but not among patients with CVD. Conclusions: No specific MC predicted risk of irAEs or OS for patients receiving IO. Increased CCI score did not predict risk of irAEs but was associated with shorter OS. This suggests IO is safe for patients with MC, but MC may limit survival benefits of IO. CVD may predict shorter OS in patients with irAEs and should be evaluated among patients receiving IO. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
235. Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
- Author
-
Wong, Alex, Riley, Maria, Zhao, Songzhu, Wang, Jing Gennie, Esguerra, Vince, Li, Mingjia, Lopez, Gabrielle, Otterson, Gregory A., Kendra, Kari, Presley, Carolyn J., Wei, Lai, Owen, Dwight H., and Ho, Kevin
- Subjects
- *
IMMUNE checkpoint inhibitors , *PNEUMONIA , *PULMONARY function tests , *COMPUTED tomography , *IPILIMUMAB , *LUNG volume measurements , *ASPIRATION pneumonia - Abstract
Background: Immune checkpoint inhibitors (ICIs) are a first-line treatment for various metastatic solid tumors. Pneumonitis is a potentially devastating complication of ICI treatment and a leading cause of ICI-related mortality. Here, we evaluate whether abnormal pre-treatment pulmonary function tests (PFTs) or interstitial abnormalities on computed tomography of the chest (CT chest) prior to ICI are associated with the development of ICI-pneumonitis (ICI-p). Methods: We conducted a retrospective cohort study of consecutive patients who received at least one dose of ICI from 2011 to 2017 at The Ohio State University. Potential risk factors for ICI-p, including abnormal PFTs and CT chest, were recorded. These risk factors were compared between patients with and without pneumonitis. Results: In total, 1097 patients were included, 46 with ICI-p and 1051 without. Ninety percent of patients had pre-treatment chest imaging, while only 10% had pre-treatment PFTs. On multivariable analysis, interstitial abnormalities and reduced total lung capacity (TLC) were significantly associated with development of ICI-p (hazard ratio of 42.42 [95% CI; 15.04–119.67] and hazard ratio of 4.04 [95% CI; 1.32–12.37]), respectively. No other PFT abnormality was associated with increased risk of ICI-p. There was no significant difference in overall survival in patients who did or did not develop ICI-p (p = 0.332). Conclusions: Pre-existing interstitial abnormalities on CT chest and reduced TLC were strongly associated with developing ICI-p. Prospective studies are warranted to further explore the role of PFTs as a potential tool for identifying patients at highest risk for developing ICI-p. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
236. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.
- Author
-
Miah, Abdul, Tinoco, Gabriel, Zhao, Songzhu, Wei, Lai, Johns, Andrew, Patel, Sandip, Li, Mingjia, Grogan, Madison, Lopez, Gabrielle, Husain, Marium, Hoyd, Rebecca, Mumtaz, Khalid, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Spakowicz, Daniel, Otterson, Gregory A., Presley, Carolyn J., and Owen, Dwight H.
- Subjects
- *
INJURY risk factors , *IMMUNE checkpoint proteins , *DISEASE risk factors , *DRUG side effects , *IPILIMUMAB , *IMMUNE checkpoint inhibitors - Abstract
Purpose: Immune checkpoint inhibitors (ICIs) are associated with a unique set of immune-related adverse events (irAEs). Few studies have evaluated the risk factors and outcomes of patients who develop ICI-induced hepatitis (ICIH). Methods: We utilized an institutional database of patients with advanced cancers treated with ICI to identify patients with ICIH. irAEs were graded using the Common Terminology Criteria for Adverse Events v4. Overall survival (OS) was calculated from the date of ICI to death from any cause or the date of the last follow-up. OS with 95% confidence intervals were estimated using the Kaplan–Meier method and stratified by the occurrence of ICIH. Results: We identified 1096 patients treated with ICI. The most common ICIs were PD1/L1 (n = 774) and CTLA-4 inhibitors (n = 195). ICIH occurred among 64 (6%) patients: severity was < grade 3 in 30 and ≥ grade 3 in 24 patients (3.1% overall). Median time to ICIH was 63 days. ICIH was more frequent in women (p = 0.038), in patients treated with combination ICIs (p < 0.001), and when given as first-line therapy (p = 0.018). Occurrence of ICIH was associated with significantly longer OS, median 37.0 months (95% CI 21.4, NR) compared to 11.3 months (95% CI 10, 13, p < 0.001); there was no difference in OS between patients with ≥ grade 3 ICIH vs grade 1–2. Conclusions: Female sex, combination immunotherapy, and the first line of immunotherapy were associated with ICIH. Patients with ICIH had improved clinical survival compared to those that did not develop ICIH. There is a need for prospective further studies to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
237. Feasibility of an embedded palliative care clinic model for patients with an advanced thoracic malignancy.
- Author
-
Bertino, Erin M., Grogan, Madison M., Benedict, Jason A., Agne, Julia L., Janse, Sarah, Eastep, Christine, Sullivan, Diana, Gast, Kelly C., Naughton, Michelle J., and Presley, Carolyn J.
- Abstract
Purpose: Early palliative care (PC) with standard oncology care has demonstrated improved patient outcomes, but multiple care delivery models are utilized. This study prospectively evaluated the feasibility of an embedded PC clinic model and collected patient-reported outcomes (PROs) and caregiver needs. Methods: In this observational study of embedded outpatient PC for patients with advanced thoracic malignancies treated at The Ohio State University Thoracic Oncology clinic, patients received same-day coordinated oncology and palliative care visits at one clinic location. PC encounters included comprehensive symptom assessment and management, advanced care planning, and goals of care discussion. Multiple study assessments were utilized. We describe the feasibility of evaluating PROs and caregiver needs in an embedded PC model. Results: Forty patients and 28 caregivers were enrolled. PROs were collected at baseline and follow-up visits. Over a 12-month follow-up, 36 patients discontinued study participation due to hospice enrollment, death, study withdrawal, or COVID restrictions. At baseline, 32 patients (80%) rated distress as moderate-severe with clinically significant depression (44%) and anxiety (36%). Survey completion rates significantly decreased over time: 3 months (24 eligible, 66% completed), 6 months (17 eligible; 41% completed), 9 months (9 eligible; 44% completed), and 12 months (4 eligible; 50% completed). Conclusion: We found that an embedded PC clinic was feasible, although there were challenges encountered in longitudinal collection of PROs due to high study attrition. Ongoing assessment and expansion of this embedded PC model will continue to identify strengths and challenges to improve patient and caregiver outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
238. Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival.
- Author
-
Andersen, Barbara L., Myers, John, Blevins, Tessa, Park, Kylie R., Smith, Rachel M., Reisinger, Sarah, Carbone, David P., Presley, Carolyn J., Shields, Peter G., and Carson, William E.
- Subjects
- *
LUNG cancer , *PNEUMONIA , *NON-small-cell lung carcinoma , *LYMPHOCYTE count , *MENTAL depression , *SARCOIDOSIS - Abstract
Lung cancer is a product of inflammation and a dysfunctional immune system, and depression has similar dysregulation. Depression disproportionately affects lung cancer patients, having the highest rates of all cancers. Systemic inflammation and depression are both predictive of non-small cell lung cancer (NSCLC) survival, but the existence and extent of any co-occurrence is unknown. Studied is the association between systemic inflammation ratio (SIR) biomarker levels and patients' depressive symptoms, with the hypothesis that depression severity would be significantly associated with prognostically poor inflammation. Newly diagnosed stage-IV non-small cell lung cancer (NSCLC; N = 186) patients were enrolled (ClinicalTrials.gov Identifier: NCT03199651) and blood draws and depression self-reports (Patient Health Questionnaire-9) were obtained. For SIRs, cell counts of neutrophils (N), lymphocytes (L), and platelets (P) were abstracted for ratio (R) calculations for NLR, PLR, and the Advanced Lung cancer Inflammation Index (ALI). Patients were followed and biomarkers were tested as predictors of 2-year overall survival (OS) to confirm their relevance. Next, multivariate linear regressions tested associations of depression with NLR, PLR, and ALI. Overall 2-year mortality was 61% (113/186). Cox model analyses confirmed higher NLR [hazard ratio (HR) = 1.91; p = 0.001] and PLR (HR = 2.08; p<0.001), along with lower ALI (HR = 0.53; p = 0.005), to be predictive of worse OS. Adjusting for covariates, depression was reliably associated with biomarker levels (p ≤ 0.02). Patients with moderate/severe depressive symptoms were 2 to 3 times more likely to have prognostically poor biomarker levels. Novel data show patients' depressive symptoms were reliably associated with lung-relevant systemic inflammation biomarkers, all assessed at diagnosis/pretreatment. The same SIRs were found prognostic for patients' 2-year OS. Intensive study of depression, combined with measures of cell biology and inflammation is needed to extend these findings to discover mechanisms of depression toxicity for NSCLC patients' treatment responses and survival. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
239. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
- Author
-
Fletcher, Kylie, Cortellini, Alessio, Ganta, Teja, Kankaria, Roma, Song, Haocan, Ye, Fei, Irlmeier, Rebecca, Debnath, Neha, Saeed, Anwaar, Radford, Maluki, Alahmadi, Asrar, Diamond, Akiva, Hoimes, Christopher, Presley, Carolyn J., Owen, Dwight H., Abou Alaiwi, Sarah, Nassar, Amin H., Lamberti, Giuseppe, Perrone, Fabiana, and Buti, Sebastiano
- Subjects
- *
TREATMENT effectiveness , *TRANSITIONAL cell carcinoma , *NON-small-cell lung carcinoma , *RENAL cell carcinoma , *OLDER patients - Abstract
Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to have decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading to early cessation of therapy. We aimed to determine whether early discontinuation impacts efficacy of anti-PD-1 therapy in patients ≥80 years old. In this retrospective, multicenter, international cohort study, we examined 773 patients with 4 tumor types who were at least 80 years old and treated with anti-PD-1 therapy. We determined response rate, overall survival (OS), and progression-free survival (PFS) in patients who discontinued therapy early (<12 months) for reasons other than progression or death. We used descriptive statistics for demographics, response, and toxicity rates. Survival statistics were described using Kaplan Meier curves. Median (range) age at anti-PD-1 initiation was 83.0 (75.8–97.0) years. The cancer types included were melanoma (n = 286), non-small cell lung cancer (NSCLC) (n = 345), urothelial cell carcinoma (UCC) (n = 108), and renal cell carcinoma (RCC) (n = 34). Of these, 102 met the primary endpoint of <12 months to discontinuation for reasons other than death or progression. Median PFS and OS, respectively, for these patients were 34.4 months and 46.6 months for melanoma, 15.8 months and 23.4 months for NSCLC, and 10.4 months and 15.8 months for UCC. This study suggests geriatric patients who have demonstrated therapeutic benefit and discontinued anti-PD-1 therapy at less than 12 months of duration for reasons other than progression may have durable clinical benefit without additional therapy. • We observed no clear difference in outcomes by treatment duration. • Early cessation in those with anti-tumor benefit may not compromise cancer outcomes. • Range of therapy duration unclear in this population, but may include short courses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
240. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival.
- Author
-
Haddad, Tyler C., Zhao, Songzhu, Li, Mingjia, Patel, Sandip H., Johns, Andrew, Grogan, Madison, Lopez, Gabriella, Miah, Abdul, Wei, Lai, Tinoco, Gabriel, Riesenberg, Brian, Li, Zihai, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Otterson, Gregory, Presley, Carolyn J., and Owen, Dwight H.
- Subjects
- *
IMMUNE checkpoint proteins , *DRUG side effects , *IMMUNE checkpoint inhibitors , *THROMBOCYTOPENIA , *THROMBOPOIETIN receptors , *OVERALL survival - Abstract
Introduction: Immune checkpoint inhibitors (ICI) are associated with unique immune-related adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an understudied and poorly understood toxicity; little data are available regarding either risk of irTCP or the effect of irTCP on clinical outcomes of patients treated with ICI. Methods: We conducted a retrospective review of sequential cancer patients treated with ICI between 2011 and 2017 at our institution. All patients who received ICI alone or in combination with other systemic therapy in any line of treatment were included; those with thrombocytopenia ≥ grade 3 at baseline were excluded. We calculated the incidence of ≥ grade 3 irTCP and overall survival (OS). Patient factors associated with irTCP were assessed. Results: We identified 1,038 patients that met eligibility criteria. Overall, 89 (8.6%) patients developed grade ≥ 3 thrombocytopenia; eighteen were attributed to ICI (1.73% overall). Patients who developed grade ≥ 3 irTCP had worse overall survival compared to those whose thrombocytopenia was unrelated to ICI (4.17 vs. 10.8 month; HR. 1.94, 95% CI 1.13, 3.33; log-rank p = 0.0164). Patients with grade ≥ 3 irTCP also had worse survival compared to those without thrombocytopenia (4.17 vs. 13.31 months; HR 2.22, 95% CI 1.36, 3.62; log-rank p = 0.001). The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy (p = 0.059) and was not associated with cancer type, smoking status, age, gender, race, or line of therapy. Conclusions: Unlike other irAEs, we found that irTCP was associated with worse overall survival. The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
241. Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study.
- Author
-
Wong, Melisa L., Shi, Ying, Smith, Alexander K., Miaskowski, Christine, Boscardin, W. John, Cohen, Harvey Jay, Lam, Vivian, Mazor, Melissa, Metzger, Lia, Presley, Carolyn J., Williams, Grant R., Loh, Kah Poh, Ursem, Carling J., Friedlander, Terence W., Blakely, Collin M., Gubens, Matthew A., Allen, Gregory, Shumay, Dianne, and Walter, Louise C.
- Subjects
- *
TREATMENT of lung tumors , *LUNG cancer treatment , *RESEARCH methodology , *CANCER chemotherapy , *GERIATRIC assessment , *INTERVIEWING , *PHYSICAL mobility , *LONGITUDINAL method , *PALLIATIVE treatment , *IMMUNOTHERAPY , *OLD age - Abstract
Background: Maintenance of function during cancer treatment is important to older adults. Characteristics associated with pretreatment life‐space mobility and changes during non‐small cell lung cancer (NSCLC) treatment remain unknown. Methods: This mixed methods cohort study recruited adults age ≥65 with advanced NSCLC starting palliative chemotherapy, immunotherapy, and/or targeted therapy from a Comprehensive Cancer Center, Veterans Affairs, and safety‐net clinic. Patients completed geriatric assessments including Life‐Space Assessment (LSA) pretreatment and at 1, 2, 4, and 6 months after treatment initiation. LSA scores range from 0 to 120 (greater mobility); LSA <60 is considered restricted. We used mixed‐effects models to examine pretreatment LSA, change from 0 to 1 month, and change from 1 to 6 months. A subgroup participated in semistructured interviews pretreatment and at 2 and 6 months to understand the patient experience of life‐space change. For each interview participant, we created joint displays of longitudinal LSA scores juxtaposed with illustrative quotes. Results: Among 93 patients, median age was 73 (range 65–94). Mean pretreatment LSA score was 67.1. On average, LSA declined 10.1 points from pretreatment to 1 month and remained stable at 6 months. Pretreatment LSA score was associated with several demographic, clinical, geriatric assessment, and symptom characteristics. LSA decline at 1 month was greater among patients with high anxiety (slope = −12.6 vs. −2.3, p = 0.048). Pretreatment body mass index <21 kg/m2 was associated with LSA improvement from 1 to 6 months (slope = 4.1 vs. −0.04, p = 0.003). Joint displays illustrated the impact of different life‐space trajectories on patients' lives in their words. Conclusion: Older adults with NSCLC have low pretreatment life space with many developing restricted life space during treatment. Incorporating life‐space assessments into clinical cancer care may help older adults concretely visualize how treatment might impact their daily function to allow for informed decision making and identify early changes in mobility to implement supportive interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
242. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.
- Author
-
Nashed, Andrew, Zhang, Shijun, Chiang, Chien-Wei, Zitu, M., Otterson, Gregory A., Presley, Carolyn J., Kendra, Kari, Patel, Sandip H., Johns, Andrew, Li, Mingjia, Grogan, Madison, Lopez, Gabrielle, Owen, Dwight H., and Li, Lang
- Subjects
- *
MEDICAL research , *NOSOLOGY , *ELECTRONIC health records , *DATA mining , *DRUG side effects , *ISCHEMIC colitis - Abstract
Background: The aim of this retrospective study was to demonstrate that irAEs, specifically gastrointestinal and pulmonary, examined through International Classification of Disease (ICD) data leads to underrepresentation of true irAEs and overrepresentation of false irAEs, thereby concluding that ICD claims data are a poor approach to electronic health record (EHR) data mining for irAEs in immunotherapy clinical research. Methods: This retrospective analysis was conducted in 1,063 cancer patients who received ICIs between 2011 and 2017. We identified irAEs by manual review of medical records to determine the incidence of each of our endpoints, namely colitis, hepatitis, pneumonitis, other irAE, or no irAE. We then performed a secondary analysis utilizing ICD claims data alone using a broad range of symptom and disease-specific ICD codes representative of irAEs. Results: 16% (n = 174/1,063) of the total study population was initially found to have either pneumonitis 3% (n = 37), colitis 7% (n = 81) or hepatitis 5% (n = 56) on manual review. Of these patients, 46% (n = 80/174) did not have ICD code evidence in the EHR reflecting their irAE. Of the total patients not found to have any irAEs during manual review, 61% (n = 459/748) of patients had ICD codes suggestive of possible irAE, yet were not identified as having an irAE during manual review. Discussion: Examining gastrointestinal and pulmonary irAEs through the International Classification of Disease (ICD) data leads to underrepresentation of true irAEs and overrepresentation of false irAEs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
243. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis.
- Author
-
Davidoff, Amy J., Canavan, Maureen E., Prsic, Elizabeth, Saphire, Maureen, Wang, Shi-Yi, and Presley, Carolyn J.
- Subjects
- *
LUNG cancer , *MEDICARE beneficiaries , *MEDICARE , *DIAGNOSIS , *SYMPTOMS , *CANCER diagnosis - Abstract
Background: Rather than early hospice enrollment, most Medicare beneficiaries receive "usual care" in the last months of life, outside of the hospice setting. While care intensity during the last weeks of life has been studied extensively, patterns of symptom management services (SMS) and/or cancer-directed therapies (CDT) received over a 6-month end-of-life period have not. Methods: This retrospective study used the Surveillance, Epidemiology, and End Results (SEER)–Medicare database to identify decedents diagnosed with lung cancer at age ≥ 66 years between January 2007 and December 2013 who survived ≥ 6 months from diagnosis. Medicare claims identified receipt of SMS and/or CDT. We created monthly indicators for care content (SMS-only, CDT-only, or both; otherwise full-month hospice or inpatient/skilled nursing). Multinomial logistic regression estimated associations between sociodemographics and comorbidity, with care content in the final month. Results: Between 6 and 1 months before death, full-month hospice and inpatient/skilled nursing increased; CDT decreased from 31.9 to 18.5%; SMS increased from 86.6 to 97.7%. Relative to full-month hospice, the percentage of patients receiving SMS-only was higher for males, unmarried, younger age, and higher comorbidity; the percentage receiving CDT was also higher for males, unmarried, and younger age, but decreased with increasing comorbidity and over calendar time. Conclusion: Among lung cancer decedents observed in the outpatient, nonhospice setting, SMS receipt increased and was nearly universal as death approached. CDT diminished dramatically over the end-of-life period. Associations between sociodemographic characteristics and care setting suggest differences in care preferences or access barriers. Claims represent an important resource for characterizing end-of-life care patterns. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
244. ASSOCIATION BETWEEN PRE-TREATMENT CHEST IMAGING AND IMMUNE CHECKPOINT INHIBITOR PNEUMONITIS IN LUNG CANCER.
- Author
-
WONG, ALEXANDER, RILEY, MARIA, ZHAO, SONGZHU, ZIMMER, JESSICA, VIVEIROS, MATTHEW, WANG, JING G, ESGUERRA, VINCENT G, LI, MINGJIA, LOPEZ, GABRIELLE, OTTERSON, GREGORY, KENDRA, KARI, PRESLEY, CAROLYN, WEI, LAI, OWEN, DWIGHT, and HO, KEVIN
- Subjects
- *
IMMUNE checkpoint inhibitors , *LUNG cancer , *PNEUMONIA - Published
- 2023
- Full Text
- View/download PDF
245. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
- Author
-
Li, Mingjia, Spakowicz, Daniel, Zhao, Songzhu, Patel, Sandip H., Johns, Andrew, Grogan, Madison, Miah, Abdul, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Wei, Lai, Carbone, David P., Otterson, Gregory A., Presley, Carolyn J., and Owen, Dwight H.
- Subjects
- *
IMMUNE checkpoint inhibitors , *PNEUMONIA , *PROPORTIONAL hazards models , *CANCER patients , *LUNG cancer - Abstract
Background: Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that may complicate treatment with immune checkpoint inhibitors (ICI) and can cause significant morbidity. We sought to identify predictors for the development of CIP, and whether the use of inhaled corticosteroids (ICS) at time of ICI may be protective. Methods: Patients with advanced cancer treated with ICI from 2011 and 2018 were included in this study. CIP attribution to ICI was determined by treating physician at time of diagnosis. Predictors were assessed by univariate and multivariable Cox proportional hazard models. Results: We identified 837 pts treated with ICI, of whom 30 (3.6%) developed grade 2 or higher CIP. 82 patients (9.8%) were receiving ICS at time of ICI and had increased risk of developing CIP with hazard ration (HR) of 4.22 (95% CI 1.93–9.21, p < 0.001) compared to those patients not receiving ICS. Patients with age ≥ 65 years had increased risk of developing CIP (HR 2.12, 95% CI 1.02–4.40, p = 0.044), as did 209 patients with lung cancer (198 NSCLC and 11 SCLC) compared to other types of cancers (HR 3.15, 95% CI 1.54–6.46, p = 0.002). In multivariable analysis, age ≥ 65 years, lung cancer diagnosis, and ICS use remained statistically associated with the development of CIP, with adjusted HR for ICS 3.09 (95% CI 1.32–7.24, p = 0.009). Conclusions: Patients treated with ICS at time of ICI initiation had an increased risk of developing CIP. We further identified older adults with age ≥ 65 years and lung cancers as independent risk factors for CIP. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
246. Patterns of pain medication use associated with reported pain interference in older adults with and without cancer.
- Author
-
Davidoff, Amy J., Canavan, Maureen E., Feder, Shelli, Wang, Shiyi, Sheinfeld, Ella, Kent, Erin E., Kapo, Jennifer, and Presley, Carolyn J.
- Subjects
- *
OLDER people , *CANCER pain , *MEDICARE Part D , *PAIN management , *DRUGS , *PAIN - Abstract
Context: Concerns about the adequacy of pain management among older adults are increasing, particularly with restrictions on opioid prescribing.Objectives: To examine associations between prescription pain medication receipt and patient-reported pain interference in older adults with and without cancer.Methods: Using the 2007-2012 Surveillance Epidemiology and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) database linked to Medicare Part D prescription claims, we selected MHOS respondents (N = 15,624) aged ≥ 66 years, ≤ 5 years of a cancer diagnosis (N = 9105), or without cancer (N = 6519). We measured receipt of opioids, non-steroidal anti-inflammatory drugs, and antiepileptics, and selected antidepressants within 30 days prior to survey. Patient-reported activity limitation due to pain (pain interference) within the past 30 days was summarized as severe, moderate, or mild/none. Logistic regression using predictive margins estimated associations between pain interference, cancer history, and pain medication receipt, adjusting for socio-demographics, chronic conditions, and Part D low-income subsidy.Results: Severe or moderate pain interference was reported by 21.3% and 46.1%, respectively. Pain medication was received by 21.5%, with 11.6% receiving opioids. Among adults reporting severe pain interference, opioid prescriptions were filled by 27.0% versus 23.8% (p = 0.040) with and without cancer, respectively. Over half (56%) of adults reporting severe pain in both groups failed to receive any prescription pain medication.Conclusions: Older adults with cancer were more likely to receive prescription pain medications compared with adults without cancer; however, many older adults reporting severe pain interference did not receive medications. Improved assessment and management of pain among older adults with and without cancer is urgently needed. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
247. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
- Author
-
Spakowicz, Daniel, Hoyd, Rebecca, Muniak, Mitchell, Husain, Marium, Bassett, James S., Wang, Lei, Tinoco, Gabriel, Patel, Sandip H., Burkart, Jarred, Miah, Abdul, Li, Mingjia, Johns, Andrew, Grogan, Madison, Carbone, David P., Verschraegen, Claire F., Kendra, Kari L., Otterson, Gregory A., Li, Lang, Presley, Carolyn J., and Owen, Dwight H.
- Subjects
- *
IMMUNE checkpoint inhibitors , *CAUSAL models , *HISTAMINE receptors , *ELECTRONIC health records , *DRUGS , *H2 receptor antagonists , *ANTIBIOTICS assay - Abstract
Background: The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we sought to broadly survey cancers to identify those in which the microbiome may play a prognostic role using retrospective analyses of patients with advanced cancer treated with ICIs.Methods: We conducted a retrospective analysis of 690 patients who received ICI therapy for advanced cancer. We used a literature review to define a causal model for the relationship between medications, the microbiome, and ICI response to guide the abstraction of electronic health records. Medications with precedent for changes to the microbiome included antibiotics, corticosteroids, proton pump inhibitors, histamine receptor blockers, non-steroid anti-inflammatories and statins. We tested the effect of medication timing on overall survival (OS) and evaluated the robustness of medication effects in each cancer. Finally, we compared the size of the effect observed for different classes of antibiotics to taxa that have been correlated to ICI response using a literature review of culture-based antibiotic susceptibilities.Results: Of the medications assessed, only antibiotics and corticosteroids significantly associated with shorter OS. The hazard ratios (HRs) for antibiotics and corticosteroids were highest near the start of ICI treatment but remained significant when given prior to ICI. Antibiotics and corticosteroids remained significantly associated with OS even when controlling for multiple factors such as Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index score, and stage. When grouping antibiotics by class, β-lactams showed the strongest association with OS across all tested cancers.Conclusions: The timing and strength of the correlations with antibiotics and corticosteroids after controlling for confounding factors are consistent with the microbiome involvement with the response to ICIs across several cancers. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
248. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
- Author
-
Burns, Laura, Hsu, Chih-Yuan, Whisenant, Jennifer G., Marmarelis, Melina E., Presley, Carolyn J., Reckamp, Karen L., Khan, Hina, Jo Fidler, Mary, Bestvina, Christine M., Brahmer, Julie, Puri, Sonam, Patel, Jyoti D., Halmos, Balazs, Hirsch, Fred R., Liu, Stephen V., Costa, Daniel B., Goldberg, Sarah B., Feldman, Lawrence E., Mamdani, Hirva, and Puc, Matthew
- Subjects
- *
COVID-19 , *BLACK people , *BLACK white differences , *RACE , *RACIAL inequality - Abstract
• Our group examined racial disparities in outcomes in patients with thoracic cancers and COVID-19 infection in North America. • Black patients with thoracic malignancies who acquire COVID-19 are at higher risk of hospitalization than their White peers. • There was no significant mortality difference between Black and White patients with thoracic cancer and COVID-19 infection. Patients with thoracic malignancies who develop COVID-19 infection have a higher hospitalization rate compared to the general population and to those with other cancer types, but how this outcome differs by race and ethnicity is relatively understudied. The TERAVOLT database is an international, multi-center repository of cross-sectional and longitudinal data studying the impact of COVID-19 on individuals with thoracic malignancies. Patients from North America with thoracic malignancies and confirmed COVID-19 infection were included for this analysis of racial and ethnic disparities. Patients with missing race data or races and ethnicities with fewer than 50 patients were excluded from analysis. Multivariable analyses for endpoints of hospitalization and death were performed on these 471 patients. Of the 471 patients, 73% were White and 27% were Black. The majority (90%) were non-Hispanic ethnicity, 5% were Hispanic, and 4% were missing ethnicity data. Black patients were more likely to have an Eastern Cooperative Oncology Group (ECOG) Performance Status ≥ 2 (p-value = 0.04). On multivariable analysis, Black patients were more likely than White patients to require hospitalization (Odds Ratio (OR): 1.69, 95% CI: 1.01–2.83, p-value = 0.044). These differences remained across different waves of the pandemic. However, no statistically significant difference in mortality was found between Black and White patients (OR 1.29, 95% CI: 0.69–2.40, p-value = 0.408). Black patients with thoracic malignancies who acquire COVID-19 infection are at a significantly higher risk of hospitalization compared to White patients, but there is no significant difference in mortality. The underlying drivers of racial disparity among patients with thoracic malignancies and COVID-19 infection require ongoing investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
249. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
- Author
-
Li, Mingjia, Spakowicz, Daniel, Burkart, Jarred, Patel, Sandip, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Carbone, David P., Verschraegen, Claire F., Presley, Carolyn J., Otterson, Gregory A., Kendra, Kari, and Owen, Dwight H.
- Subjects
- *
PROPORTIONAL hazards models , *BODY mass index , *LYMPHOCYTES - Abstract
Background: The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients with advanced cancers treated with immune checkpoint inhibitors (ICI), but has generally been evaluated as a single threshold value at baseline. We evaluated NLR at baseline and within first month during treatment in patients who received ICI for advanced cancer to evaluate the prognostic value of baseline and of changes from baseline to on-treatment NLR. Methods: A retrospective review of patients with advanced cancer treated with ICI from 2011 to 2017 at the Ohio State University was performed. NLR was calculated at the initiation of ICI and repeated at median of 21 days. Overall survival (OS) was calculated from the initiation of ICI to date of death or censored at last follow-up. Significance of Cox proportional hazards models were evaluated by log-rank test. Calculations were performed using the survival and survminer packages in R, and SPSS. Results: 509 patients were identified and included in the analysis. Patients with baseline and on-treatment NLR < 5 had significantly longer OS (P < 0.001). The change in NLR overtime was a predictor of OS and was observed to be non-linear in nature. This property remained statistically significant with P < 0.05 after adjusting for age, body mass index, sex, cancer type, performance status, and days to repeat NLR measurement. Patients with a moderate decrease in NLR from baseline had the longest OS of 27.8 months (95% CI 21.8–33.8). Patients with significant NLR decrease had OS of 11.4 months (95% CI 6.1–16.7). Patients with a significant increase in NLR had the shortest OS of 5.0 months (95% CI 0.9–9.1). Conclusions: We confirmed the prognostic value of NLR in patients with advanced cancer treated with ICIs. We found that change in NLR over time is a non-linear predictor of patient outcomes. Patients who had moderate decrease in NLR during treatment with ICI were found to have the longest survival, whereas a significant decrease or increase in NLR was associated with shorter survival. To our knowledge, this is the first study to demonstrate a non-linear change in NLR over time that correlates with survival. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
250. Information Needs of Older Women With Early-Stage Breast Cancer When Making Radiation Therapy Decisions.
- Author
-
Wang, Shi-Yi, Kelly, Gabrielle, Gross, Cary, Killelea, Brigid K., Mougalian, Sarah, Presley, Carolyn, Fraenkel, Liana, and Evans, Suzanne B.
- Subjects
- *
HEALTH of older women , *BREAST cancer , *RADIOTHERAPY , *DECISION making , *ADJUVANT treatment of cancer , *AGE distribution , *BREAST tumors , *FAMILIES , *FRIENDSHIP , *PATIENT education , *PHYSICIANS , *PROGNOSIS , *QUALITY of life , *RESEARCH funding , *OCCUPATIONAL roles , *SOCIOECONOMIC factors , *LUMPECTOMY , *PSYCHOLOGY , *CANCER & psychology - Abstract
Purpose: To identify the information older women with early-stage breast cancer need when making radiation therapy decisions, and who patients identify as the main decision maker.Methods and Materials: We surveyed (through face-to-face interview, telephone, or mail) women aged ≥65 years who received lumpectomy and were considering or receiving adjuvant radiation therapy for early-stage breast cancer. The survey instrument was constructed with input from patient and professional advisory committees, including breast cancer survivors, advocates of breast cancer care and aging, clinicians, and researchers. Participants rated the importance (on a 4-point scale) of 24 statements describing the benefits, side effects, impact on daily life, and other issues of radiation therapy in relation to radiation therapy decision making. Participants also designated who was considered the key decision maker.Results: The response rate was 56.4% (93 of 165). Mean age was 72.5 years, ranging from 65 to 93 years. More than 96% of participants indicated they were the main decision maker on receiving radiation therapy. There was wide variation in information needs regarding radiation therapy decision making. Participants rated a mean of 18 (range, 3-24) items as "essential." Participants rated items related to benefits highest, followed by side effects. Participants who were older than 75 years rated 13.9 questions as essential, whereas participants aged ≤74 years rated 18.7 as essential (P=.018).Conclusions: Older women desire information and have more agency and input in the decision-making process than prior literature would suggest. The variation in information needs indicates that future decision support tools should provide options to select what information would be of interest to the participants. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.